2025-01-20
Litchlab Accelerates Innovation in Antibody-Drug Conjugates (ADCs) for Targeted Oncology Therapies
Litchlab, a global leader in advanced drug delivery technologies, is expanding its capabilities in Antibody-Drug Conjugates (ADCs), a transformative class of precision oncology treatments. With deep expertise in high-potency API synthesis, conjugation chemistr...